Depomedroxyprogesterone acetate therapy for hot flashes in survivors of breast cancer: no unfavorable impact on recurrence and survival

  • Natalie M. Ertz-ArchambaultEmail author
  • Lana B. Rogoff
  • Heidi E. Kosiorek
  • Brenda J. Ernst
  • Karen S. Anderson
  • Barbara A. Pockaj
  • Richard J. Gray
  • Donald W. Northfelt
Original Article



Survivors of estrogen receptor–expressing breast cancer generally do not receive estrogen-based therapy for menopausal symptoms due to concern for provoking recurrence of disease. Single-dose depomedroxyprogesterone acetate has been shown to be among the most effective non-estrogen strategies for treatment of menopausal hot flashes, but long-term evidence for safety in survivors is lacking.


We conducted an institutional review board approved, retrospective, case-control cohort study at a tertiary, academic referral center. Patients with estrogen receptor-expressing early-stage operable breast cancer who received depomedroxyprogesterone acetate for hot flashes between January 2005 and December 2012 were identified. We confirmed 75 patients who met strict inclusion criteria who were matched 1:1 with controls for age, stage of disease, HER2 status, and year of diagnosis. Overall survival, loco-regional recurrence-free survival, and progression-free survival assessments for cases were compared with controls.


Median follow-up duration was 68.4 months in cases and 57.6 months in controls. Estimated local-regional recurrence-free survival at 10 years was 97% (95% CI, 92–100%) in cases and 98% (95% CI, 95–100%) in controls. Estimated progression-free survival at 10 years was 89% (95% CI, 80–100%) in cases and 83% (95% CI, 73–95) in controls. The majority (75%) of case patients experienced satisfactory relief of hot flashes from depomedroxyprogesterone injection.


In this retrospective case-control study, we were unable to identify a detrimental effect of depomedroxyprogesterone acetate therapy for hot flashes in survivors of estrogen receptor–expressing breast cancer. Depomedroxyprogesterone acetate may be acceptable for management of hot flashes in this population.


Hot flashes Breast neoplasms Survivors Medroxyprogesterone acetate 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–1717Google Scholar
  2. 2.
    Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R, Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381(9869):805–816CrossRefGoogle Scholar
  3. 3.
    Finck G, Barton DL, Loprinzi CL, Quella SK, Sloan JA (1998) Definitions of hot flashes in breast cancer survivors. J Pain Symptom Manag 16(5):327–333CrossRefGoogle Scholar
  4. 4.
    Carpenter JS (2000) Hot flashes and their management in breast cancer. Semin Oncol Nurs 16(3):214–225CrossRefGoogle Scholar
  5. 5.
    Stein KD, Jacobsen PB, Hann DM, Greenberg H, Lyman G (2000) Impact of hot flashes on quality of life among postmenopausal women being treated for breast cancer. J Pain Symptom Manag 19(6):436–445CrossRefGoogle Scholar
  6. 6.
    Stan D, Loprinzi CL, Ruddy KJ (2013) Breast cancer survivorship issues. Hematol Oncol Clin North Am 27(4):805–827 ixCrossRefGoogle Scholar
  7. 7.
    Barton DL, Loprinzi CL, Quella SK, Sloan JA, Veeder MH, Egner JR, Fidler P, Stella PJ, Swan DK, Vaught NL, Novotny P (1998) Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol 16(2):495–500CrossRefGoogle Scholar
  8. 8.
    Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, LaVasseur BI, Barton DL, Novotny PJ, Dakhil SR, Rodger K, Rummans TA, Christensen BJ (2000) Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet. 356(9247):2059–2063CrossRefGoogle Scholar
  9. 9.
    Steinberg KK, Thacker SB, Smith S et al (1991) A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA. 265(15):1985–1990CrossRefGoogle Scholar
  10. 10.
    Holmberg L, Anderson H, HABITS steering and data monitoring committees (2004) HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial stopped. Lancet 363(9407):453–455Google Scholar
  11. 11.
    Rutqvist LE, Johansson H, Stockholm Breast Cancer Study Group (2007) Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer. Acta Oncol 46(2):133–145CrossRefGoogle Scholar
  12. 12.
    Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A, WHI Investigators (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: The women's health initiative randomized trial. JAMA. 289(24):3243–3253CrossRefGoogle Scholar
  13. 13.
    Sideras K, Loprinzi CL (2010) Nonhormonal management of hot flashes for women on risk reduction therapy. J Natl Compr Cancer Netw 8(10):1171–1179CrossRefGoogle Scholar
  14. 14.
    L’Esperance S, Frenette S, Dionne A, Dionne JY, Comite de l’evolution des pratiques en oncologie (2013) Pharmacological and non-hormonal treatment of hot flashes in breast cancer survivors: CEPO review and recommendations. Support Care Cancer 21(5):1461–1474CrossRefGoogle Scholar
  15. 15.
    Binkhorst L, Mathijssen RH, van Herk-Sukel MP et al (2013) Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen. Breast Cancer Res Treat 139(3):923–929CrossRefGoogle Scholar
  16. 16.
    Loprinzi CL, Levitt R, Barton D, Sloan JA, Dakhil SR, Nikcevich DA, Bearden JD III, Mailliard JA, Tschetter LK, Fitch TR, Kugler JW (2006) Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: north central cancer treatment group trial N99C7. J Clin Oncol 24(9):1409–1414CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Natalie M. Ertz-Archambault
    • 1
    Email author
  • Lana B. Rogoff
    • 1
  • Heidi E. Kosiorek
    • 2
  • Brenda J. Ernst
    • 1
  • Karen S. Anderson
    • 1
  • Barbara A. Pockaj
    • 3
  • Richard J. Gray
    • 3
  • Donald W. Northfelt
    • 1
  1. 1.Division of Hematology and Medical OncologyMayo ClinicPhoenixUSA
  2. 2.Department of Health Sciences ResearchMayo ClinicScottsdaleUSA
  3. 3.Department of General SurgeryMayo ClinicPhoenixUSA

Personalised recommendations